Scientists are confronted with a perennial dilemma of whether it is worthwhile to invest their effort further on a molecule. Similarly, organizations also need significant assurance that it is worthwhile to invest hard earned revenues on a molecule. Late stage failures not only negatively impacts research productivity of the organization but also results in competitive disadvantage due to time gone waste.
If you have compounds that show an early promise but subsequent costs are substantial to move them further into development pipeline, we can help you with a 360° evaluation of their suitability for their intended objective.
This research is carried out by expert VLife scientists who have a sterling track record in discovery of new indications and is enabled by our computational technologies and a multi core parallel processing computational cluster.
Our expertise in computational discovery Success with computation technology requires awareness of not only its strengths but also of the areas where it needs augmentation from other approaches. Being developers of computational technologies, we have proved our expertise by creating IP in 3 NCE classes and 7 new indication discoveries.
Wide diversity of experience We cater to a variety of sectors and within them, a diversity of areas. e.g. in pharmaceuticals, we have successfully delivered discovery projects in oncology, anti-fungal, diabetes, CNS etc.
State-of-art technology portfolio Clients benefit from the whole range of VLife's technologies having validated algorithms, published innovations and efficient workflows which are accessible to clients through VLife services.
In-house custom development skills Generic technologies sometimes are inadequate or inefficient in complex research. For such needs, our in-house team has skills to develop custom technologies ensuring reliable research.